



14 April 2021

**Proteome Sciences plc
("Proteome Sciences" or the "Company")**

Director/PDMR Shareholding

The Company has received notification from Richard Dennis, Chief Commercial Officer, that on 12 April and 13 April 2021 he purchased, in aggregate, 625,000 Ordinary Shares in the Company at an average price of 5.22p per share. Richard Dennis now holds 625,000 Ordinary Shares in the Company, which represents approximately 0.21% of the issued share capital of the Company.

The below notification is made in accordance with the requirements of the UK Market Abuse Regulation.

1.	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name:	Richard Dennis						
	Reason for the notification							
a)	Position/status:	Chief Commercial Officer and Executive Director						
b)	Initial notification/Amendment:	Initial Notification						
	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name:	Proteome Sciences Plc						
b)	LEI:	213800Q62ICXANKU2986						
	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument: Identification code:	Ordinary Shares of 1p nominal value GB0003104196						
b)	Nature of the transaction:	Purchase of Ordinary Shares						
c)	Price(s) and volume(s):	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>5.29p</td> <td>125,000</td> </tr> <tr> <td>5.23p</td> <td>125,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	5.29p	125,000	5.23p	125,000
Price(s)	Volume(s)							
5.29p	125,000							
5.23p	125,000							

		5.23p	125,000
		5.14p	250,000
d)	Aggregated information: <ul style="list-style-type: none"> • Aggregated volume: • Price: 	Single transaction as in 4 c) above	
		Average Price	Volume(s)
		5.22p	625,000
e)	Date of the transaction:	12 and 13 April 2021	
f)	Place of the transaction:	London Stock Exchange, AIM (XLON)	

For further information please contact:

Proteome Sciences plc

Mariola Soehngen M.D., Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer

Tel: +44 (0)20 7043 2116

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter – Corporate Finance
Tony Quirke – Sales and Corporate Broking

Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.